Myelomonocytic Leukemia
Oncology·MeSH: Leukemia
Prevalence
0.5 / 100K
9 drugs in development·5 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
Phase 3(3)
Phase 2(3)
Phase 1(1)
| Drug | Company |
|---|---|
| Imetelstat | Assertio Holdings, Inc. (ASRT) |
Preclinical(1)
| Drug | Company |
|---|---|
| lenzilumab | HUMANIGEN, INC (HGEN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Myelomonocytic Leukemia?
BioSniper tracks 9 drugs in development for Myelomonocytic Leukemia across 5 companies.
How many clinical trials target Myelomonocytic Leukemia?
There are 1 clinical trial targeting Myelomonocytic Leukemia tracked by BioSniper.
What is the prevalence of Myelomonocytic Leukemia?
The estimated prevalence of Myelomonocytic Leukemia is approximately 0.5 per 100,000 population.
Deep-dive into Myelomonocytic Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis